APA (7th ed.) Citation

Westin, J., Burke, J. M., Chapman, A. E., Kilavuz, T., Xu, C., Shmuely, Y., & Radford, J. (2022). PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9). Wiley.

Chicago Style (17th ed.) Citation

Westin, J., J. M. Burke, A. E. Chapman, T. Kilavuz, C. Xu, Y. Shmuely, and J. Radford. PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9). Wiley, 2022.

MLA (9th ed.) Citation

Westin, J., et al. PB2146: A PHASE 2, OPEN-LABEL STUDY OF LONCASTUXIMAB TESIRINE IN COMBINATION WITH RITUXIMAB (LONCA-R) IN PREVIOUSLY UNTREATED UNFIT/FRAIL PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL) (LOTIS-9). Wiley, 2022.